ketamine has been researched along with Depression, Endogenous in 158 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 9.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| "BACKGROUND This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression." | 9.34 | Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy. ( Liu, P; Peng, S; Wang, J; Wang, Y; Xu, F; Xu, X, 2020) |
| "The results of this pilot study are inconclusive because they lack power to support an advantage of ketamine anesthesia compared with methohexital in ameliorating depressive symptoms for electroconvulsive therapy." | 9.24 | A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression. ( Eads, LA; Golden, K; Han, X; Ray-Griffith, SL; Stowe, ZN, 2017) |
| "Ketamine has been shown to be efficacious for the treatment of depression, specifically among individuals who do not respond to first-line treatments." | 9.05 | Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. ( George, TP; Lowe, DJE; Müller, DJ, 2020) |
| "Glutamatergic modulators may have therapeutic potential in the treatment of depressive disorder (DD), riluzole, as a modulating drug of the glutamatergic system, its antidepressant efficacy and safety of riluzole for DD are inconsistent." | 9.05 | Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. ( Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M, 2020) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 8.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| "Narrative review of the literature on the efficacy and safety of subanaesthetic doses of ketamine for the treatment of depression." | 8.89 | Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. ( Glue, P; Katalinic, N; Lai, R; Loo, CK; Mitchell, PB; Somogyi, A, 2013) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 8.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication." | 7.88 | Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. ( Dunlop, BW; Edwards, JA; Galendez, GC; Garlow, SJ; Job, GP; McDonald, WM; Reiff, CM; Riva-Posse, P; Saah, TC, 2018) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 7.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| " Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety." | 7.76 | Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. ( Iglewicz, A; Irwin, SA, 2010) |
| " Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine." | 7.01 | Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. ( Gu, HW; Guo, J; Hashimoto, K; Qiu, D; Wang, XM; Yang, JJ; Zhang, GF, 2023) |
| "Intravenous racemic ketamine is a promising treatment for treatment-resistant depression." | 5.94 | Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis ( Endo, K; Kodama, W; Terao, I; Tsuge, T, 2024) |
| "Ketamine use has become of increasing concern because it has spread in many parts of the world during the past few years." | 5.62 | Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users. ( Hsu, CY; Wang, PW; Wu, HC; Yang, YY; Yen, CF, 2021) |
| "Depression affects over 121 million people annually worldwide." | 5.51 | Magnesium and ketamine in the treatment of depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "BACKGROUND This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression." | 5.34 | Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy. ( Liu, P; Peng, S; Wang, J; Wang, Y; Xu, F; Xu, X, 2020) |
| "The results of this pilot study are inconclusive because they lack power to support an advantage of ketamine anesthesia compared with methohexital in ameliorating depressive symptoms for electroconvulsive therapy." | 5.24 | A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression. ( Eads, LA; Golden, K; Han, X; Ray-Griffith, SL; Stowe, ZN, 2017) |
| "PubMed, MEDLINE, and Cochrane reviews were queried for articles related to keywords ketamine, suicidality, suicidal ideation, and emergency department/room." | 5.12 | Ketamine for acute suicidality in the emergency department: A systematic review. ( Bullard, T; Maguire, L; Papa, L, 2021) |
| "Glutamatergic modulators may have therapeutic potential in the treatment of depressive disorder (DD), riluzole, as a modulating drug of the glutamatergic system, its antidepressant efficacy and safety of riluzole for DD are inconsistent." | 5.05 | Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. ( Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M, 2020) |
| "Ketamine has been shown to be efficacious for the treatment of depression, specifically among individuals who do not respond to first-line treatments." | 5.05 | Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. ( George, TP; Lowe, DJE; Müller, DJ, 2020) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 4.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| "Narrative review of the literature on the efficacy and safety of subanaesthetic doses of ketamine for the treatment of depression." | 4.89 | Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. ( Glue, P; Katalinic, N; Lai, R; Loo, CK; Mitchell, PB; Somogyi, A, 2013) |
| " The reported effects of the use of mushrooms containing psilocybin by a number of cultures around the world has stimulated several trials showing beneficial effects of a single dose of psilocybin for over a year in healthy people, and for up to 3 months in patients with anxiety disorders who have advanced cancer." | 4.89 | Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. ( Young, SN, 2013) |
| "Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has well-described rapid antidepressant effects in clinical studies of individuals with treatment-resistant major depressive disorder (MDD)." | 4.89 | Ketamine, sleep, and depression: current status and new questions. ( Duncan, WC; Zarate, CA, 2013) |
| "Although ketamine can rapidly decrease suicidal ideation (SI), its neurobiological mechanism of action remains unclear." | 4.31 | Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions. ( Chen, X; Hu, Y; Luo, X; Ning, Y; Wang, M; Yuan, S; Zhang, B; Zhou, Y, 2023) |
| "Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder." | 4.31 | Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression. ( Gan, Y; Hu, Z; Lan, X; Li, N; Li, W; Liu, H; Ning, Y; Wang, C; Wu, Z; Ye, Y; Zhang, F; Zhou, Y, 2023) |
| " Levels of the three markers did not correlate with ketamine use variables, craving, depression, or anxiety symptoms." | 3.96 | Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation. ( Chang, HM; Chen, CH; Chen, CK; Chen, LY; Huang, MC; Lin, SK; Xu, K, 2020) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "Ketamine has been shown to induce a rapid antidepressant effect on patients with depression." | 3.91 | Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. ( Pałucha-Poniewiera, A; Pilc, A; Podkowa, K, 2019) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "The efficacy of ketamine to alleviate depressive symptoms has promoted a wealth of research exploring alternate therapeutic targets for depression." | 3.88 | Interactive effects of ghrelin and ketamine on forced swim performance: Implications for novel antidepressant strategies. ( Abizaid, A; Dwyer, Z; Hayley, S; Landrigan, J; Shawaf, F, 2018) |
| "The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication." | 3.88 | Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. ( Dunlop, BW; Edwards, JA; Galendez, GC; Garlow, SJ; Job, GP; McDonald, WM; Reiff, CM; Riva-Posse, P; Saah, TC, 2018) |
| " Also, they displayed higher levels of blood serum corticosterone, as well as decreased body weight." | 3.88 | Vicarious Social Defeat Stress Induces Depression-Related Outcomes in Female Mice. ( Alipio, JB; Braren, SH; Castillo, SA; Flores-Ramirez, FJ; Garcia-Carachure, I; Hernandez, MA; Iñiguez, SD; Lobo, MK; Riggs, LM; Sanchez, DO; Serrano, PA, 2018) |
| " Emerging data has identified certain drugs such as ketamine as rapidly-acting antidepressants for major depressive disorder and TRD." | 3.85 | Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. ( Anderson, WH; Catlow, JT; Felder, CC; Higgs, RE; Kuo, MS; Laksmanan, A; Li, X; Martin, AE; Nikolayev, A; Schober, DA; Tolstikov, VV; Witkin, JM, 2017) |
| "The use of ketamine in research and treatment of depressive disorders is controversial." | 3.83 | Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. ( Harris, KM; Ho, RC; Zhang, MW, 2016) |
| "The aim of the present study was to investigate the effects of ketamine, imipramine, and ketamine plus imipramine on chronic depression-like behaviors of Wistar Kyoto (WKY) rats and underlying mechanism." | 3.83 | [Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats]. ( Jin, XJ; Li, QQ; Peng, LC; Ye, K, 2016) |
| "The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepressants since this drug causes rapid-onset and sustained antidepressant effects in treatment resistant patients with depression." | 3.83 | Ketamine's antidepressant action: beyond NMDA receptor inhibition. ( Hashimoto, K, 2016) |
| "Clinical studies demonstrate that the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in patients with refractive major depressive disorder and bipolar depression." | 3.79 | Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. ( Dang, YH; Gao, CG; Hashimoto, K; Jia, M; Ma, R; Ma, XC; Wang, F; Wu, J, 2013) |
| " Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety." | 3.76 | Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. ( Iglewicz, A; Irwin, SA, 2010) |
| " Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine." | 3.01 | Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies. ( Gu, HW; Guo, J; Hashimoto, K; Qiu, D; Wang, XM; Yang, JJ; Zhang, GF, 2023) |
| "Ketamine was administered by IV (n = 4), IM (n = 5) or SC (n = 6) injection." | 2.82 | Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. ( Gálvez, V; Glue, P; Hadzi-Pavlovic, D; Harper, S; Lai, R; Leyden, J; Loo, CK; Mitchell, PB; O'Keefe, E; Somogyi, AA; Weickert, CS, 2016) |
| "Ketamine has many properties that make it an interesting candidate for rapidly treating depression and anxiety in patients receiving hospice care." | 2.78 | Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. ( Carr, CH; Iglewicz, A; Irwin, SA; Lloyd, LS; Lo, JY; Nelesen, RA; Romero, SD, 2013) |
| "Ketamine was initially used as an anesthetic which could induce cognitive impairment and psychomimetic effects." | 2.72 | Increased use of ketamine for the treatment of depression: Benefits and concerns. ( Kim, YK; Na, KS, 2021) |
| "Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation." | 2.70 | Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. ( Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001) |
| " Notably, the dosage of ketamine for antidepressive action is comparable to the dose that can generate schizophrenia-like psychotic symptoms." | 2.66 | Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. ( Fukuyama, K; Kawano, Y; Motomura, E; Okada, M; Shiroyama, T, 2020) |
| "Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings." | 2.55 | Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. ( Andrade, C, 2017) |
| "Ketamine was always superior to placebo." | 2.55 | Administration of ketamine for unipolar and bipolar depression. ( Bartova, L; Carlberg, L; Gryglewski, G; Kasper, S; Kraus, C; Lanzenberger, R; Papageorgiou, K; Popovic, A; Rabl, U; Rybakowski, JK; Spies, M; Vanicek, T; Willeit, M; Winkler, D, 2017) |
| "Ketamine use has become of increasing concern because it has spread in many parts of the world during the past few years." | 1.62 | Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users. ( Hsu, CY; Wang, PW; Wu, HC; Yang, YY; Yen, CF, 2021) |
| "Patients with poor seizure quality may benefit from lower propofol doses, which are applicable by the addition of ketamine." | 1.62 | Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality. ( Aksay, SS; Beuschlein, J; Bumb, JM; Janke, C; Karl, S; Kranaster, L; Pfeifer, AM; Remennik, D; Sartorius, A, 2021) |
| " Furthermore, most currently available medications need several weeks to achieve therapeutic effects, and the long-term use of these drugs is often associated with significant unwanted side effects and resultant reductions in treatment compliance." | 1.62 | Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. ( Baker, G; Dos Santos, RG; Dursun, S; Hallak, JE, 2021) |
| "The esketamine treatment schedule involved a maximum of 3× weekly dosing at 0." | 1.56 | Urothelial toxicity of esketamine in the treatment of depression. ( Bauer, M; Cleare, A; Findeis, H; Ritter, P; Sauer, C, 2020) |
| "Depression affects over 121 million people annually worldwide." | 1.51 | Magnesium and ketamine in the treatment of depression. ( Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A, 2019) |
| "This will promote the research and treatment of pruritus and depression." | 1.48 | The behavioral study on the interactive aggravation between pruritus and depression. ( Bai, Y; Feng, YP; Li, H; Wang, XD; Yang, G, 2018) |
| "Ketamine is a non-competitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 1.48 | Downregulation of Egr-1 Expression Level via GluN2B Underlies the Antidepressant Effects of Ketamine in a Chronic Unpredictable Stress Animal Model of Depression. ( Liu, CC; Lv, YD; Sun, WY; Tian, LJ; Wang, HH; Zhang, WJ, 2018) |
| "(R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine." | 1.48 | Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model. ( Dong, C; Hashimoto, K; Ma, M; Qu, Y; Ren, Q; Yang, C; Zhang, JC, 2018) |
| "(R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine." | 1.46 | Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. ( Dong, C; Fujita, Y; Hashimoto, K; Ma, M; Qu, Y; Ren, Q; Yang, C, 2017) |
| "Tramadol is an analgesic agent that is mainly used to treat moderate to severe pain." | 1.46 | Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test. ( Akbarian, R; Chamanara, M; Dehpour, AR; Ghasemi, M; Imran-Khan, M; Norouzi-Javidan, A; Ostadhadi, S, 2017) |
| "To mimic PTSD we employed the inescapable footshock protocol." | 1.46 | Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF. ( Bertoldi, K; Costa Da Costa, J; Greggio, S; Jeckel, CMM; Mestriner, RG; Neves, LT; Saur, L; Schallenberger, B; Siqueira, IR; Venturin, GT; Xavier, LL, 2017) |
| "Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors." | 1.43 | Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. ( du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016) |
| "Agmatine has antidepressant properties in rodent models of depression, and agmatinase (Agmat), the agmatine-degrading enzyme, is upregulated in the brains of mood disorder patients." | 1.43 | Involvement of the agmatinergic system in the depressive-like phenotype of the Crtc1 knockout mouse model of depression. ( Breuillaud, L; Cardinaux, JR; Halfon, O; Luthi-Carter, R; Magistretti, PJ; Meylan, EM; Seredenina, T, 2016) |
| " Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants." | 1.43 | Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. ( Aghajanian, GK; Duman, RS; Krystal, JH; Sanacora, G, 2016) |
| " However, a long term use of ketamine tends to elicit its adverse reactions." | 1.42 | Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. ( Guo, J; Liu, WX; Qiu, LL; Sun, HL; Wang, XM; Yang, JJ; Zhang, GF; Zhou, ZQ, 2015) |
| "Dextromethorphan (DM) is an antitussive with rapid acting antidepressant potential based on pharmacodynamic similarities to ketamine." | 1.42 | Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. ( Matsumoto, RR; Nguyen, L, 2015) |
| " The dose-response relationships of all 3 compounds in the forced swim test were also investigated in mice 30 min after IP administration." | 1.42 | Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. ( Drabik, U; Gajdosz, R; Librowski, T; Nowak, G; Popik, P; Sałat, K; Siwek, A; Starowicz, G, 2015) |
| "A 42 year-old woman with breast cancer and major depression resistant to medical treatment received a 90 minute intravenous infusion of 0." | 1.39 | [Effect of sub-anaesthetic doses of ketamine in the postoperative period in a patient with uncontrolled depression]. ( Alférez-García, I; Alonso-Menoyo, MB; Carricondo-Martínez, MA; Cortiñas-Saenz, M; Errando-Oyonarte, CL, 2013) |
| " Assessments of psychological wellbeing showed greater dissociative symptoms in frequent users and a dose-response effect on delusional symptoms, with frequent users scoring higher than infrequent, abstinent users and non-users, respectively." | 1.36 | Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. ( Curran, HV; Morgan, CJ; Muetzelfeldt, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (3.16) | 29.6817 |
| 2010's | 126 (79.75) | 24.3611 |
| 2020's | 27 (17.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, PW | 1 |
| Yen, CF | 1 |
| Wu, HC | 1 |
| Hsu, CY | 1 |
| Yang, YY | 1 |
| Lima, TM | 1 |
| Visacri, MB | 1 |
| Aguiar, PM | 1 |
| Ma, X | 1 |
| Yang, S | 2 |
| Zhang, Z | 1 |
| Liu, L | 2 |
| Shi, W | 1 |
| Li, S | 2 |
| Cai, X | 1 |
| Zhou, Q | 2 |
| Malikowska-Racia, N | 2 |
| Golebiowska, J | 2 |
| Nikiforuk, A | 2 |
| Khoo, SY | 2 |
| Popik, P | 3 |
| Guo, J | 2 |
| Qiu, D | 1 |
| Gu, HW | 1 |
| Wang, XM | 2 |
| Hashimoto, K | 15 |
| Zhang, GF | 3 |
| Yang, JJ | 4 |
| Chen, X | 1 |
| Zhang, B | 1 |
| Yuan, S | 1 |
| Luo, X | 1 |
| Wang, M | 1 |
| Hu, Y | 1 |
| Zhou, Y | 3 |
| Ning, Y | 3 |
| Wu, Z | 1 |
| Gan, Y | 1 |
| Li, N | 1 |
| Lan, X | 1 |
| Wang, C | 2 |
| Zhang, F | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Ye, Y | 1 |
| Hu, Z | 1 |
| Terao, I | 1 |
| Tsuge, T | 1 |
| Endo, K | 1 |
| Kodama, W | 1 |
| Krimmel, SR | 1 |
| Zanos, P | 3 |
| Georgiou, P | 1 |
| Colloca, L | 1 |
| Gould, TD | 3 |
| Górska, N | 2 |
| Słupski, J | 2 |
| Szałach, ŁP | 1 |
| Włodarczyk, A | 1 |
| Szarmach, J | 1 |
| Jakuszkowiak-Wojten, K | 1 |
| Gałuszko-Węgielnik, M | 2 |
| Wilkowska, A | 1 |
| Wiglusz, MS | 2 |
| Cubała, WJ | 2 |
| Yao, R | 1 |
| Wang, H | 1 |
| Yuan, M | 1 |
| Wang, G | 2 |
| Wu, C | 1 |
| Jiménez Treviño, L | 1 |
| Velasco, Á | 1 |
| Rodríguez-Revuelta, J | 1 |
| Saiz, P | 1 |
| Lowe, DJE | 1 |
| Müller, DJ | 1 |
| George, TP | 1 |
| Malhi, GS | 1 |
| Morris, G | 1 |
| Bell, E | 1 |
| Hamilton, A | 1 |
| Abdallah, CG | 2 |
| Krystal, JH | 5 |
| Lavender, E | 1 |
| Hirasawa-Fujita, M | 1 |
| Domino, EF | 1 |
| Stenovec, M | 1 |
| Li, B | 1 |
| Verkhratsky, A | 1 |
| Zorec, R | 1 |
| Wang, J | 3 |
| Wang, Y | 3 |
| Xu, X | 1 |
| Peng, S | 1 |
| Xu, F | 2 |
| Liu, P | 1 |
| Sartorius, A | 1 |
| Beuschlein, J | 1 |
| Remennik, D | 1 |
| Pfeifer, AM | 1 |
| Karl, S | 1 |
| Bumb, JM | 1 |
| Aksay, SS | 1 |
| Kranaster, L | 1 |
| Janke, C | 1 |
| Findeis, H | 1 |
| Sauer, C | 1 |
| Cleare, A | 1 |
| Bauer, M | 1 |
| Ritter, P | 1 |
| Na, KS | 1 |
| Kim, YK | 1 |
| Okada, M | 1 |
| Kawano, Y | 1 |
| Fukuyama, K | 1 |
| Motomura, E | 1 |
| Shiroyama, T | 1 |
| Kadriu, B | 1 |
| Greenwald, M | 1 |
| Henter, ID | 1 |
| Gilbert, JR | 1 |
| Kraus, C | 2 |
| Park, LT | 1 |
| Zarate, CA | 3 |
| Maguire, L | 1 |
| Bullard, T | 1 |
| Papa, L | 1 |
| Preskorn, SH | 1 |
| Lins-Silva, DH | 1 |
| Vieira, F | 1 |
| Souza-Marques, B | 1 |
| Jesus-Nunes, AP | 1 |
| Quarantini, LC | 1 |
| Dos Santos, RG | 1 |
| Hallak, JE | 1 |
| Baker, G | 1 |
| Dursun, S | 1 |
| Carreno, FR | 1 |
| Collins, GT | 1 |
| Frazer, A | 1 |
| Lodge, DJ | 1 |
| Ren, L | 3 |
| Chen, G | 3 |
| Orozco-Solis, R | 1 |
| Montellier, E | 1 |
| Aguilar-Arnal, L | 1 |
| Sato, S | 1 |
| Vawter, MP | 1 |
| Bunney, BG | 2 |
| Bunney, WE | 2 |
| Sassone-Corsi, P | 1 |
| Ryan, CJ | 1 |
| Loo, C | 1 |
| Ray-Griffith, SL | 1 |
| Eads, LA | 1 |
| Han, X | 1 |
| Golden, K | 1 |
| Stowe, ZN | 1 |
| Ekstrand, J | 1 |
| Movahed, P | 1 |
| Andrade, C | 2 |
| van Wissen, K | 1 |
| Blanchard, D | 1 |
| Yang, C | 7 |
| Ren, Q | 3 |
| Qu, Y | 4 |
| Zhang, JC | 1 |
| Ma, M | 5 |
| Dong, C | 4 |
| Wilkinson, ST | 1 |
| Toprak, M | 1 |
| Turner, MS | 1 |
| Levine, SP | 1 |
| Katz, RB | 1 |
| Sanacora, G | 7 |
| Ostadhadi, S | 1 |
| Norouzi-Javidan, A | 1 |
| Chamanara, M | 1 |
| Akbarian, R | 1 |
| Imran-Khan, M | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 1 |
| Kasper, S | 2 |
| Morgan, PT | 1 |
| Saur, L | 1 |
| Neves, LT | 1 |
| Greggio, S | 1 |
| Venturin, GT | 1 |
| Jeckel, CMM | 1 |
| Costa Da Costa, J | 1 |
| Bertoldi, K | 1 |
| Schallenberger, B | 1 |
| Siqueira, IR | 1 |
| Mestriner, RG | 1 |
| Xavier, LL | 1 |
| Jiang, Y | 1 |
| Sun, X | 1 |
| Lian, B | 2 |
| Sun, H | 1 |
| Du, Z | 1 |
| Li, Q | 3 |
| Sun, L | 1 |
| Iñiguez, SD | 1 |
| Flores-Ramirez, FJ | 1 |
| Riggs, LM | 1 |
| Alipio, JB | 1 |
| Garcia-Carachure, I | 1 |
| Hernandez, MA | 1 |
| Sanchez, DO | 1 |
| Lobo, MK | 1 |
| Serrano, PA | 1 |
| Braren, SH | 1 |
| Castillo, SA | 1 |
| Huang, BS | 2 |
| Liston, C | 2 |
| Jiang, C | 1 |
| Lin, WJ | 1 |
| Sadahiro, M | 1 |
| Labonté, B | 2 |
| Menard, C | 1 |
| Pfau, ML | 1 |
| Tamminga, CA | 2 |
| Turecki, G | 1 |
| Nestler, EJ | 2 |
| Russo, SJ | 1 |
| Salton, SR | 1 |
| Yan, W | 1 |
| Liu, JF | 1 |
| Han, Y | 1 |
| Zhang, W | 1 |
| Luo, YX | 1 |
| Xue, YX | 1 |
| Zhu, WL | 1 |
| Chen, WH | 1 |
| Guo, HL | 1 |
| Ma, YN | 1 |
| Yuan, K | 1 |
| Wang, JS | 1 |
| Shi, J | 1 |
| Lu, L | 1 |
| Fujita, Y | 2 |
| Zhang, WJ | 1 |
| Wang, HH | 2 |
| Lv, YD | 1 |
| Liu, CC | 1 |
| Sun, WY | 1 |
| Tian, LJ | 1 |
| Vulser, H | 1 |
| Vulser, C | 1 |
| Rieutord, M | 1 |
| Passeron, A | 1 |
| Lefebvre, D | 1 |
| Baup, E | 1 |
| Seigneurie, AS | 1 |
| Thauvin, I | 1 |
| Limosin, F | 1 |
| Lemogne, C | 1 |
| Phillips, AG | 1 |
| Geyer, MA | 1 |
| Robbins, TW | 1 |
| Riva-Posse, P | 1 |
| Reiff, CM | 1 |
| Edwards, JA | 1 |
| Job, GP | 1 |
| Galendez, GC | 1 |
| Garlow, SJ | 1 |
| Saah, TC | 1 |
| Dunlop, BW | 1 |
| McDonald, WM | 1 |
| Widman, AJ | 1 |
| McMahon, LL | 1 |
| Freedman, R | 1 |
| Brown, AS | 1 |
| Cannon, TD | 1 |
| Druss, BG | 1 |
| Earls, FJ | 1 |
| Escobar, J | 1 |
| Hurd, YL | 1 |
| Lewis, DA | 1 |
| López-Jaramillo, C | 1 |
| Luby, J | 1 |
| Mayberg, HS | 1 |
| Moffitt, TE | 1 |
| Oquendo, M | 1 |
| Perlis, RH | 1 |
| Pine, DS | 1 |
| Rush, AJ | 1 |
| Tohen, M | 1 |
| Vieta, E | 1 |
| Wisner, KL | 1 |
| Xin, Y | 1 |
| Xia, J | 1 |
| Yang, X | 2 |
| Zhou, C | 1 |
| Gong, X | 1 |
| Gui, S | 1 |
| Mao, Q | 1 |
| Wang, L | 1 |
| Li, P | 1 |
| Huang, C | 1 |
| Qi, X | 1 |
| Xie, P | 2 |
| Yamaguchi, JI | 1 |
| Toki, H | 1 |
| Koike, H | 1 |
| Mizuno-Yasuhira, A | 1 |
| Chaki, S | 2 |
| Williams, AV | 1 |
| Trainor, BC | 1 |
| Kim, D | 1 |
| Cheong, E | 1 |
| Shin, HS | 1 |
| Chou, D | 1 |
| Peng, HY | 1 |
| Lin, TB | 1 |
| Lai, CY | 1 |
| Hsieh, MC | 1 |
| Wen, YC | 1 |
| Lee, AS | 1 |
| Yang, PS | 1 |
| Chen, GD | 1 |
| Ho, YC | 1 |
| Mishra, PK | 1 |
| Kumar, A | 1 |
| Behar, KL | 1 |
| Patel, AB | 1 |
| De Feyter, HM | 1 |
| Averill, LA | 1 |
| Jiang, L | 1 |
| Averill, CL | 1 |
| Chowdhury, GMI | 1 |
| Purohit, P | 1 |
| de Graaf, RA | 1 |
| Esterlis, I | 1 |
| Juchem, C | 1 |
| Pittman, BP | 1 |
| Rothman, DL | 1 |
| Mason, GF | 1 |
| Zhang, K | 5 |
| Steelman, BC | 1 |
| Cover, KK | 1 |
| Kerkhoff, WG | 1 |
| Mathur, BN | 1 |
| Deng, J | 1 |
| Min, S | 1 |
| Peng, L | 1 |
| Chen, Q | 1 |
| Tian, Z | 1 |
| Chang, L | 3 |
| Wang, XD | 1 |
| Yang, G | 1 |
| Bai, Y | 1 |
| Feng, YP | 1 |
| Li, H | 3 |
| Willner, P | 1 |
| Gruca, P | 1 |
| Lason, M | 1 |
| Tota-Glowczyk, K | 1 |
| Litwa, E | 1 |
| Niemczyk, M | 1 |
| Papp, M | 1 |
| Zheng, W | 1 |
| Liu, W | 2 |
| Zhan, Y | 1 |
| Chen, L | 1 |
| Li, M | 1 |
| De Berardis, D | 1 |
| Fornaro, M | 1 |
| Valchera, A | 1 |
| Cavuto, M | 1 |
| Perna, G | 1 |
| Di Nicola, M | 1 |
| Serafini, G | 1 |
| Carano, A | 1 |
| Pompili, M | 1 |
| Vellante, F | 1 |
| Orsolini, L | 1 |
| Fiengo, A | 1 |
| Ventriglio, A | 1 |
| Yong-Ku, K | 1 |
| Martinotti, G | 1 |
| Di Giannantonio, M | 1 |
| Tomasetti, C | 1 |
| Harkin, A | 1 |
| McLoughlin, DM | 1 |
| Xiong, Z | 2 |
| Ishima, T | 1 |
| Pu, Y | 2 |
| Chen, J | 2 |
| Chu, X | 1 |
| Huang, N | 1 |
| Hua, D | 1 |
| Zhan, G | 1 |
| Zhu, B | 1 |
| Jiang, R | 1 |
| Yang, L | 1 |
| Bi, J | 1 |
| Xu, H | 1 |
| Luo, A | 1 |
| Pałucha-Poniewiera, A | 1 |
| Podkowa, K | 1 |
| Pilc, A | 1 |
| Wang, W | 2 |
| Gao, H | 1 |
| Tang, QK | 1 |
| Yin, LY | 1 |
| Yin, XY | 1 |
| Hao, JR | 1 |
| Geng, DQ | 1 |
| Gao, C | 1 |
| Cui, Y | 1 |
| Hu, S | 1 |
| Hu, H | 1 |
| Clayton, AR | 1 |
| Duman, RS | 3 |
| Moda-Sava, RN | 1 |
| Murdock, MH | 1 |
| Parekh, PK | 1 |
| Fetcho, RN | 1 |
| Huynh, TN | 1 |
| Witztum, J | 1 |
| Shaver, DC | 1 |
| Rosenthal, DL | 1 |
| Alway, EJ | 1 |
| Lopez, K | 1 |
| Meng, Y | 1 |
| Nellissen, L | 1 |
| Grosenick, L | 1 |
| Milner, TA | 1 |
| Deisseroth, K | 1 |
| Bito, H | 1 |
| Kasai, H | 1 |
| Köhler-Forsberg, O | 1 |
| Cusin, C | 1 |
| Nierenberg, AA | 1 |
| Jaworska, N | 1 |
| Phillips, JL | 1 |
| Huang, MC | 1 |
| Chen, CH | 1 |
| Chen, LY | 1 |
| Chang, HM | 1 |
| Chen, CK | 1 |
| Lin, SK | 1 |
| Xu, K | 1 |
| Katalinic, N | 1 |
| Lai, R | 2 |
| Somogyi, A | 1 |
| Mitchell, PB | 2 |
| Glue, P | 2 |
| Loo, CK | 2 |
| Irwin, SA | 2 |
| Iglewicz, A | 2 |
| Nelesen, RA | 1 |
| Lo, JY | 1 |
| Carr, CH | 1 |
| Romero, SD | 1 |
| Lloyd, LS | 1 |
| Duncan, WC | 1 |
| Vinberg, M | 1 |
| Hjerrild, S | 1 |
| Bjerre, J | 2 |
| Pedersen, RH | 1 |
| Videbech, P | 1 |
| McIntyre, RS | 1 |
| Cha, DS | 1 |
| Kim, RD | 1 |
| Mansur, RB | 1 |
| Flight, MH | 1 |
| Réus, GZ | 2 |
| Vieira, FG | 1 |
| Abelaira, HM | 2 |
| Michels, M | 1 |
| Tomaz, DB | 1 |
| dos Santos, MA | 1 |
| Carlessi, AS | 2 |
| Neotti, MV | 1 |
| Matias, BI | 2 |
| Luz, JR | 1 |
| Dal-Pizzol, F | 1 |
| Quevedo, J | 2 |
| Wanderer, JP | 1 |
| Rathmell, JP | 1 |
| Tang, WK | 1 |
| Morgan, CJ | 2 |
| Lau, GC | 1 |
| Liang, HJ | 1 |
| Tang, A | 1 |
| Ungvari, GS | 1 |
| Jing, L | 1 |
| Toledo-Salas, JC | 1 |
| Xu, L | 1 |
| Lepack, AE | 1 |
| Fuchikami, M | 1 |
| Dwyer, JM | 1 |
| Banasr, M | 1 |
| Franceschelli, A | 1 |
| Sens, J | 1 |
| Herchick, S | 1 |
| Thelen, C | 1 |
| Pitychoutis, PM | 1 |
| Titus, SE | 1 |
| Ignácio, ZM | 1 |
| da Luz, JR | 1 |
| Bruchchen, L | 1 |
| Florentino, D | 1 |
| Vieira, A | 1 |
| Petronilho, F | 1 |
| Schatzberg, AF | 1 |
| Wu, Q | 1 |
| Xie, L | 1 |
| Gong, W | 1 |
| Zhang, J | 1 |
| Zheng, P | 1 |
| Ji, Y | 1 |
| Wang, T | 1 |
| Li, X | 2 |
| Fang, L | 1 |
| Yang, D | 1 |
| Li, J | 1 |
| Melgiri, ND | 1 |
| Shively, C | 1 |
| Liu, WX | 2 |
| Qiu, LL | 1 |
| Sun, HL | 1 |
| Zhou, ZQ | 3 |
| Nguyen, L | 1 |
| Matsumoto, RR | 1 |
| Vogt, MA | 1 |
| Vogel, AS | 1 |
| Pfeiffer, N | 1 |
| Gass, P | 2 |
| Inta, D | 1 |
| da Frota Ribeiro, CM | 1 |
| Hoffman, R | 1 |
| Ostroff, R | 2 |
| Sałat, K | 1 |
| Siwek, A | 1 |
| Starowicz, G | 1 |
| Librowski, T | 1 |
| Nowak, G | 1 |
| Drabik, U | 1 |
| Gajdosz, R | 1 |
| Xie, ZM | 1 |
| Xu, N | 1 |
| Jia, M | 2 |
| Romeo, B | 1 |
| Choucha, W | 1 |
| Fossati, P | 1 |
| Rotge, JY | 1 |
| Ji, L | 1 |
| Zhang, MW | 2 |
| Ho, RC | 2 |
| Harris, KM | 1 |
| Xia, B | 1 |
| Zhang, H | 2 |
| Xue, W | 2 |
| Tao, W | 2 |
| Chen, C | 1 |
| Wu, R | 1 |
| Tang, J | 1 |
| Wu, H | 1 |
| Cai, B | 1 |
| Doronc, R | 1 |
| Ye, K | 1 |
| Li, QQ | 1 |
| Jin, XJ | 1 |
| Peng, LC | 1 |
| Aghajanian, GK | 1 |
| Saba, G | 1 |
| Nieto, I | 1 |
| Bation, R | 1 |
| Allaïli, N | 1 |
| Bennabi, D | 1 |
| Moliere, F | 1 |
| Richieri, R | 1 |
| Holtzmann, J | 1 |
| Bubrovszky, M | 1 |
| Camus, V | 1 |
| Charpeaud, T | 1 |
| Courtet, P | 1 |
| Courvoisier, P | 1 |
| Haesebaert, F | 1 |
| Doumy, O | 1 |
| El-Hage, W | 1 |
| Garnier, M | 1 |
| d'Amato, T | 1 |
| Bougerol, T | 1 |
| Lançon, C | 1 |
| Haffen, E | 1 |
| Llorca, PM | 1 |
| Vaiva, G | 1 |
| Bellivier, F | 1 |
| Leboyer, M | 1 |
| Aouizerate, B | 1 |
| Gálvez, V | 1 |
| O'Keefe, E | 1 |
| Hadzi-Pavlovic, D | 1 |
| Leyden, J | 1 |
| Harper, S | 1 |
| Somogyi, AA | 1 |
| Weickert, CS | 1 |
| Mallick, F | 1 |
| McCullumsmith, CB | 1 |
| Gong, T | 1 |
| Xue, L | 1 |
| Sun, Y | 1 |
| Wang, F | 2 |
| Zhong, X | 1 |
| He, H | 1 |
| Zhang, C | 1 |
| Wang, Z | 1 |
| Jiang, M | 1 |
| Zhang, M | 1 |
| Huang, X | 1 |
| du Jardin, KG | 1 |
| Liebenberg, N | 1 |
| Müller, HK | 1 |
| Elfving, B | 1 |
| Sanchez, C | 1 |
| Wegener, G | 1 |
| Meylan, EM | 1 |
| Breuillaud, L | 1 |
| Seredenina, T | 1 |
| Magistretti, PJ | 1 |
| Halfon, O | 1 |
| Luthi-Carter, R | 1 |
| Cardinaux, JR | 1 |
| Landrigan, J | 1 |
| Shawaf, F | 1 |
| Dwyer, Z | 1 |
| Abizaid, A | 1 |
| Hayley, S | 1 |
| Murrough, JW | 3 |
| Bagot, RC | 1 |
| Cates, HM | 1 |
| Purushothaman, I | 1 |
| Vialou, V | 1 |
| Heller, EA | 1 |
| Yieh, L | 1 |
| Peña, CJ | 1 |
| Shen, L | 1 |
| Wittenberg, GM | 1 |
| Bonnet, U | 1 |
| Rabl, U | 1 |
| Vanicek, T | 1 |
| Carlberg, L | 1 |
| Popovic, A | 1 |
| Spies, M | 1 |
| Bartova, L | 1 |
| Gryglewski, G | 1 |
| Papageorgiou, K | 1 |
| Lanzenberger, R | 1 |
| Willeit, M | 1 |
| Winkler, D | 1 |
| Rybakowski, JK | 1 |
| Abe, M | 1 |
| Nozawa, D | 1 |
| Nagayasu, K | 1 |
| Martin, AE | 1 |
| Schober, DA | 1 |
| Nikolayev, A | 1 |
| Tolstikov, VV | 1 |
| Anderson, WH | 1 |
| Higgs, RE | 1 |
| Kuo, MS | 1 |
| Laksmanan, A | 1 |
| Catlow, JT | 1 |
| Felder, CC | 1 |
| Witkin, JM | 1 |
| Muetzelfeldt, L | 1 |
| Curran, HV | 1 |
| Horacek, J | 1 |
| Brunovsky, M | 1 |
| Novak, T | 1 |
| Tislerova, B | 1 |
| Palenicek, T | 1 |
| Bubenikova-Valesova, V | 1 |
| Spaniel, F | 1 |
| Koprivova, J | 1 |
| Mohr, P | 1 |
| Balikova, M | 1 |
| Hoschl, C | 1 |
| De La Torre, R | 1 |
| Fontenay, C | 1 |
| Hansen, G | 1 |
| Jensen, SB | 1 |
| Hilden, T | 1 |
| Paslakis, G | 1 |
| Deuschle, M | 1 |
| Mathew, SJ | 1 |
| Shah, A | 1 |
| Lapidus, K | 1 |
| Clark, C | 1 |
| Jarun, N | 1 |
| Ostermeyer, B | 1 |
| Blier, P | 1 |
| Zigman, D | 1 |
| Blier, J | 1 |
| Laje, G | 1 |
| Lally, N | 1 |
| Mathews, D | 1 |
| Brutsche, N | 1 |
| Chemerinski, A | 1 |
| Akula, N | 1 |
| Kelmendi, B | 1 |
| Simen, A | 1 |
| McMahon, FJ | 1 |
| Zarate, C | 1 |
| Cortiñas-Saenz, M | 1 |
| Alonso-Menoyo, MB | 1 |
| Errando-Oyonarte, CL | 1 |
| Alférez-García, I | 1 |
| Carricondo-Martínez, MA | 1 |
| Coppola, M | 1 |
| Mondola, R | 1 |
| Charney, DS | 1 |
| Strakowski, SM | 1 |
| Shah, MM | 1 |
| Young, SN | 1 |
| Ma, XC | 1 |
| Dang, YH | 1 |
| Ma, R | 1 |
| Wu, J | 1 |
| Gao, CG | 1 |
| Kudoh, A | 2 |
| Gonzales, M | 1 |
| Tsai, GE | 1 |
| Krupitsky, EM | 1 |
| Burakov, AM | 1 |
| Romanova, TN | 1 |
| Grinenko, NI | 1 |
| Grinenko, AY | 1 |
| Fletcher, J | 1 |
| Petrakis, IL | 1 |
| Takahira, Y | 1 |
| Katagai, H | 1 |
| Takazawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.[NCT03473431] | 90 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder: A Randomized, Group Sequential, Adaptive Design, Controlled Clinical Trial[NCT05181527] | Phase 4 | 60 participants (Actual) | Interventional | 2022-02-10 | Completed | ||
| Effect of S-ketamine on Depressed Patients Undergoing Electroconvulsive Therapy-a Randomized, Double-blind, Controlled Clinical Study[NCT04399070] | 150 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | |||
| A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.[NCT03887624] | Early Phase 1 | 16 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to Participates could not stand the side effects) | ||
| Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152] | Phase 2/Phase 3 | 172 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| A Randomised Controlled Trial Evaluating the Efficacy and Mechanisms of a Ketogenic Diet as an Adjunctive Treatment for People With Treatment-resistant Depression[NCT06091163] | 100 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial[NCT03336541] | Phase 4 | 64 participants (Actual) | Interventional | 2017-11-23 | Completed | ||
| Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder[NCT05357040] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | ||
| A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial[NCT03272698] | Phase 4 | 62 participants (Anticipated) | Interventional | 2017-09-01 | Recruiting | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Double-blinded, Randomized Placebo-controlled Trial of 40 Hz Light Neurostimulation Therapy for Patients With Depression[NCT05680220] | 60 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| A Study of Ketamine as an Antidepressant[NCT01441505] | Phase 2 | 42 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Ketamine Frequency Treatment for Major Depressive Disorder[NCT00646087] | Phase 4 | 0 participants (Actual) | Interventional | 2008-03-31 | Withdrawn (stopped due to Pilot study determined that this study would not be feasible.) | ||
| Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial[NCT03666494] | Phase 4 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
46 reviews available for ketamine and Depression, Endogenous
| Article | Year |
|---|---|
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Meta-Analysis as Topic; Randomized Con | 2022 |
Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Pain; Pain, Postoperative; | 2023 |
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Tr | 2024 |
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Ketamine; Male; Middl | 2020 |
Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine | 2020 |
A New Paradigm for Achieving a Rapid Antidepressant Response.
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Quinolones; Thiophenes | 2020 |
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Topics: Animals; Antidepressive Agents; Depressive Disorder; Ketamine; Neuronal Plasticity; Secondary Preven | 2020 |
Ketamine's dose related multiple mechanisms of actions: Dissociative anesthetic to rapid antidepressant.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Re | 2020 |
Astrocytes in rapid ketamine antidepressant action.
Topics: Animals; Antidepressive Agents; Astrocytes; Calcium Signaling; Cholesterol; Depressive Disorder; Hom | 2020 |
Increased use of ketamine for the treatment of depression: Benefits and concerns.
Topics: Antidepressive Agents; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketami | 2021 |
Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions.
Topics: Animals; Depressive Disorder; Drug Dosage Calculations; Humans; Ketamine; Receptors, N-Methyl-D-Aspa | 2020 |
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.
Topics: Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; Hallucinogens; Humans | 2021 |
Ketamine for acute suicidality in the emergency department: A systematic review.
Topics: Adolescent; Adult; Aged; Depressive Disorder; Emergency Service, Hospital; Excitatory Amino Acid Ant | 2021 |
Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials.
Topics: Administration, Intranasal; Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive D | 2021 |
Rapid antidepressant effects of Yueju: A new look at the function and mechanism of an old herbal medicine.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Drugs, Chinese Herbal; Humans; Ketamine; Time F | 2017 |
Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine | 2017 |
Ketamine and Other Glutamate Receptor Modulators for Depression in Bipolar Disorder in Adults.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2017 |
Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review.
Topics: Depressive Disorder; Excitatory Amino Acid Antagonists; Female; Hospitals, General; Humans; Ketamine | 2018 |
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention D | 2018 |
Mechanisms of ketamine action as an antidepressant.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; | 2018 |
The impact of sex as a biological variable in the search for novel antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Female; Humans; Ketamine; Male; Receptors, N-Me | 2018 |
Overcoming Depression by Inhibition of Neural Burst Firing.
Topics: Anhedonia; Animals; Behavior, Animal; Calcium Channels, T-Type; Depressive Disorder; Disease Models, | 2018 |
A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder; Humans; Ketamine; Rec | 2019 |
Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis.
Topics: Analgesics; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Ketamine; Male | 2018 |
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.
Topics: Depressive Disorder; Humans; Ketamine; Mood Disorders; Suicidal Ideation; Suicide Prevention | 2018 |
An update on ketamine and its two enantiomers as rapid-acting antidepressants.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Ketamine | 2019 |
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Habenula; Humans; Ketamine; Recepto | 2019 |
My Struggle To Access Lifesaving Mental Health Care.
Topics: Adult; Critical Illness; Depressive Disorder; Female; Health Services Accessibility; Humans; Ketamin | 2019 |
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Topics: Animals; Antidepressive Agents; Brain; Cerebral Cortex; Depressive Disorder; gamma-Aminobutyric Acid | 2019 |
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Topics: Animals; Antidepressive Agents; Brain; Cerebral Cortex; Depressive Disorder; gamma-Aminobutyric Acid | 2019 |
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Topics: Animals; Antidepressive Agents; Brain; Cerebral Cortex; Depressive Disorder; gamma-Aminobutyric Acid | 2019 |
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Topics: Animals; Antidepressive Agents; Brain; Cerebral Cortex; Depressive Disorder; gamma-Aminobutyric Acid | 2019 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Treatment Outcome | 2013 |
Ketamine, sleep, and depression: current status and new questions.
Topics: Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder; Electroencephalography; Excitato | 2013 |
[Ketamine for treatment of acute depression].
Topics: Acute Disease; Analgesics, Short-Acting; Anesthetics, Dissociative; Antidepressive Agents; Bipolar D | 2013 |
A review of FDA-approved treatment options in bipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Co | 2013 |
Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder; Excitatory Amino Acid Antagonists; Gluta | 2015 |
Issues encountered in recent attempts to develop novel antidepressant agents.
Topics: Antidepressive Agents; Benzofurans; Deep Brain Stimulation; Depressive Disorder; Drug Discovery; Hum | 2015 |
Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 2015 |
[Other therapeutic strategies].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Central Nervous System Stimulants; Depressive Diso | 2016 |
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.
Topics: Depression; Depressive Disorder; Humans; Ketamine; Mood Disorders; Receptors, N-Methyl-D-Aspartate; | 2016 |
How much alcohol is in ketamine's antidepressant action?
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Brain; Depressive Disorder; Dopamine; Eth | 2017 |
Administration of ketamine for unipolar and bipolar depression.
Topics: Bipolar Disorder; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2017 |
Elucidation of the Role of Dorsal Raphe Serotonergic Neurons in Mood Regulation Using Pharmacological and Viral Vector-based Approaches.
Topics: Animals; Benzodiazepines; Brain; Depressive Disorder; Dorsal Raphe Nucleus; Electrophysiology; Genet | 2017 |
[The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Excitatory Amino Acid | 2011 |
Rapid-acting antidepressant strategies: mechanisms of action.
Topics: Depressive Disorder; Humans; Ketamine; Sleep Deprivation; Time Factors | 2012 |
Ketamine for treatment-resistant unipolar depression: current evidence.
Topics: Antidepressive Agents; Cognition; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Dru | 2012 |
Is there anything really novel on the antidepressant horizon?
Topics: Antidepressive Agents; Depressive Disorder; Drug Discovery; Excitatory Amino Acid Antagonists; Human | 2012 |
Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.
Topics: Affect; Anesthetics, Dissociative; Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety Dis | 2013 |
8 trials available for ketamine and Depression, Endogenous
| Article | Year |
|---|---|
Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Carcinoma; Depression; Depressive D | 2020 |
A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression.
Topics: Adult; Aged; Anesthesia; Anesthesia, Intravenous; Anesthetics, Dissociative; Anesthetics, Intravenou | 2017 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Anxiety Agents; Ant | 2013 |
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; | 2016 |
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; | 2016 |
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; | 2016 |
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; | 2016 |
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression.
Topics: Adolescent; Adult; Affect; Aged; Anesthetics, Intravenous; Cognition Disorders; Combined Modality Th | 2016 |
Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect.
Topics: Adult; Affect; Anesthetics, Dissociative; Biomarkers; Cross-Over Studies; Depressive Disorder; Doubl | 2010 |
Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Topics: Adult; Affect; Alcoholism; Anxiety; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Ty | 2001 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
Small-dose ketamine improves the postoperative state of depressed patients.
Topics: Adult; Anesthesia, General; Anesthetics, Dissociative; Blood Loss, Surgical; Depressive Disorder; Fe | 2002 |
104 other studies available for ketamine and Depression, Endogenous
| Article | Year |
|---|---|
Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users.
Topics: Depression; Depressive Disorder; Humans; Ketamine; Quality of Life; Sex Factors | 2021 |
Rapid and sustained restoration of astrocytic functions by ketamine in depression model mice.
Topics: Animals; Antidepressive Agents; Astrocytes; Brain-Derived Neurotrophic Factor; Depression; Depressiv | 2022 |
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Ketamine; Male; Rats; Reinforcement | 2023 |
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Ketamine; Male; Rats; Reinforcement | 2023 |
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Ketamine; Male; Rats; Reinforcement | 2023 |
Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Ketamine; Male; Rats; Reinforcement | 2023 |
Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Female; Gyrus Cinguli; Humans; Infus | 2023 |
Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression.
Topics: Bipolar Disorder; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; | 2023 |
Classical conditioning of antidepressant placebo effects in mice.
Topics: Animals; Antidepressive Agents; Conditioning, Classical; Depressive Disorder; Disease Models, Animal | 2020 |
Magnesium and ketamine in the treatment of depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Humans; K | 2019 |
Old drugs, new medication.
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Suicide Prevention | 2020 |
Empirical ratio of the combined use of S-ketamine and propofol in electroconvulsive therapy and its impact on seizure quality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia; Anesthetics, Intravenous; Depressive Disorde | 2021 |
Urothelial toxicity of esketamine in the treatment of depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; | 2020 |
Letter to the editor about "comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression".
Topics: Anhedonia; Bipolar Disorder; Depressive Disorder; Humans; Ketamine | 2021 |
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Evaluation, Preclinical; | 2021 |
Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Hippocampus; Imidazoles; Ketamine; Lidocaine; P | 2017 |
A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex.
Topics: Animals; Antidepressive Agents; Circadian Rhythm Signaling Peptides and Proteins; Computational Biol | 2017 |
The practicalities and ethics of ketamine for depression.
Topics: Depression; Depressive Disorder; Humans; Ketamine | 2017 |
[Warning against over-interpretation of the Swedish Agency for Health Technology Assessment and Assessment of Social Services conclusions about ketamine].
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Meta-Analysis as Topic; Sweden | 2017 |
Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Topics: Aminoacetonitrile; Animals; Antidepressive Agents; Brain; Chronic Disease; Depressive Disorder; Dise | 2018 |
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Health Care Surveys; | 2017 |
Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dizocilpine Maleate; Do | 2017 |
Editorial.
Topics: Animals; Antipsychotic Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketam | 2017 |
Ketamine and Sleep: Bridging the Gap in the Treatment of Depressive Illness.
Topics: Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine; Sleep | 2017 |
Ketamine promotes increased freezing behavior in rats with experimental PTSD without changing brain glucose metabolism or BDNF.
Topics: Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder; Disease Mo | 2017 |
Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model.
Topics: Animals; Antidepressive Agents; Behavior Rating Scale; Behavior, Animal; Depressive Disorder; Diseas | 2017 |
Vicarious Social Defeat Stress Induces Depression-Related Outcomes in Female Mice.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Body Weight; Chlordiazepoxide; Corticosterone; D | 2018 |
Cortex-wide optical imaging and network analysis of antidepressant effects.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Ketamine; M | 2017 |
VGF function in depression and antidepressant efficacy.
Topics: Adult; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2018 |
Protein kinase Mζ in medial prefrontal cortex mediates depressive-like behavior and antidepressant response.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Disease Models, Animal; Excitatory | 2018 |
Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder; Disease Models, Animal; Gastrointestinal | 2017 |
Downregulation of Egr-1 Expression Level via GluN2B Underlies the Antidepressant Effects of Ketamine in a Chronic Unpredictable Stress Animal Model of Depression.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Depressive Disorder; Disease Models, Animal; Disks | 2018 |
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
Topics: Anesthetics, Dissociative; Antidepressive Agents; Blood Pressure; Depression; Depressive Disorder; E | 2018 |
Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.
Topics: Action Potentials; Animals; Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antago | 2018 |
Can a Framework Be Established for the Safe Use of Ketamine?
Topics: Depression; Depressive Disorder; Double-Blind Method; Humans; Ketamine; Substance-Related Disorders; | 2018 |
Mechanisms of ketamine on mice hippocampi shown by gas chromatography-mass spectrometry-based metabolomic analysis.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Excitatory Amino Acid A | 2018 |
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
Topics: Animals; Antidepressive Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; | 2018 |
(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
Topics: Animals; Antidepressive Agents; Cell Membrane; Cytosol; Depressive Disorder; Disease Models, Animal; | 2018 |
Subanesthetic ketamine reverses neuronal and astroglial metabolic activity deficits in a social defeat model of depression.
Topics: Acetates; Analgesics; Animals; Astrocytes; Carbon Isotopes; Depressive Disorder; Disease Models, Ani | 2018 |
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Energy Metabolism; Excitatory Amino Acid An | 2018 |
Role of Inflammatory Bone Markers in the Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.
Topics: Animals; Antidepressive Agents; Biomarkers; Depressive Disorder; Disease Models, Animal; Dominance-S | 2018 |
The best defense is a strong offense: preventing alcohol abstinence-induced depression.
Topics: Alcohol Abstinence; Depression; Depressive Disorder; Ethanol; Humans; Ketamine | 2018 |
Lack of Antidepressant Effects of Low-Voltage-Sensitive T-Type Calcium Channel Blocker Ethosuximide in a Chronic Social Defeat Stress Model: Comparison with (R)-Ketamine.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Depressive Disor | 2018 |
The behavioral study on the interactive aggravation between pruritus and depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Chloroquine; Depression; Depressive Disorder; Dise | 2018 |
Role of copper in depression. Relationship with ketamine treatment.
Topics: Anesthetics; Animals; Antidepressive Agents; Copper; Depressive Disorder; Glutamic Acid; Hippocampus | 2018 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Ketamine and depression: A special kase for kynurenic acid?
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Kynurenic Acid; K | 2019 |
Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2019 |
Preliminary validation of natural depression in macaques with acute treatments of the fast-acting antidepressant ketamine.
Topics: Animals; Antidepressive Agents; Conditioning, Operant; Depressive Disorder; Disease Models, Animal; | 2019 |
Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression.
Topics: Actinobacteria; Animals; Antidepressive Agents; Behavior, Animal; Biomarkers; Depression; Depressive | 2019 |
Choosing the Primary Outcome in Electroconvulsive Therapy Trials and the Art of Asking When, Besides What.
Topics: Anesthesia; Depression; Depressive Disorder; Electroconvulsive Therapy; Humans; Ketamine | 2019 |
Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
Topics: Amino Acids; Animals; Antidepressive Agents; Azepines; Benzamides; Depression; Depressive Disorder; | 2019 |
Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice.
Topics: Animals; Anxiety; Corticosterone; Depression; Depressive Disorder; Disease Models, Animal; Gene Expr | 2019 |
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
Topics: Animals; Antidepressive Agents; Corticosterone; Dendritic Spines; Depressive Disorder; Disease Model | 2019 |
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model.
Topics: Animals; Antidepressive Agents; Biomarkers; Bone Density; Depression; Depressive Disorder; Disease M | 2019 |
Evolving Issues in the Treatment of Depression.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Depressive Disorder; Depressive Disorder, Major; Di | 2019 |
Harnessing Neuroimaging to Enhance Our Understanding of the Effects of Ketamine in Depression.
Topics: Brain; Depression; Depressive Disorder; Humans; Ketamine; Neuroimaging | 2019 |
Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.
Topics: Adrenocorticotropic Hormone; Adult; Anxiety; Case-Control Studies; Craving; Depressive Disorder; Fem | 2020 |
[Ketamine for treatment of depression?].
Topics: Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine | 2013 |
Trial watch: phase II boost for glutamate-targeted antidepressants.
Topics: Antidepressive Agents; Clinical Trials, Phase II as Topic; Depressive Disorder; Drug Delivery System | 2013 |
MAPK signaling correlates with the antidepressant effects of ketamine.
Topics: Aniline Compounds; Animals; Antidepressive Agents; Benzamides; Blotting, Western; Brain; Brain-Deriv | 2014 |
Ketamine as an antidepresessant: a brief research history.
Topics: Antidepressive Agents; Depressive Disorder; Excitatory Amino Acid Antagonists; History, 20th Century | 2014 |
Psychiatric morbidity in ketamine users attending counselling and youth outreach services.
Topics: Adolescent; Adult; Anxiety Disorders; Comorbidity; Counseling; Depressive Disorder; Excitatory Amino | 2015 |
Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
Topics: Antidepressive Agents; Biomarkers; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; K | 2014 |
BDNF release is required for the behavioral actions of ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Calcium Channel Blockers; Calcium | 2014 |
Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Chronic Disease; Depressive Disorder; Disease Models, | 2015 |
A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Catalase; Depressive Disorder; Disease Models, Ani | 2015 |
Macaques exhibit a naturally-occurring depression similar to humans.
Topics: Animals; Behavior, Animal; Depressive Disorder; Discriminant Analysis; Disease Models, Animal; Femal | 2015 |
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, A | 2015 |
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Dextromethorphan; | 2015 |
Role of the nitric oxide donor sodium nitroprusside in the antidepressant effect of ketamine in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dose-Response Relations | 2015 |
The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms: To the Editor.
Topics: Depressive Disorder; Female; Humans; Ketamine; Mental Status Schedule; Middle Aged; Psychotic Disord | 2016 |
Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.
Topics: Administration, Oral; Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; D | 2015 |
Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.
Topics: Animals; Antidepressive Agents; Apoptosis; Astrocytes; Behavior, Animal; Brain-Derived Neurotrophic | 2016 |
The Role of Nitric Oxide in the Antidepressant Actions of 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside in Insulin-Resistant Mice.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Animals; Antidepressive Agents; Combined Modality Ther | 2016 |
The paroxetine controversy: lessons for ketamine trials.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Double-Blin | 2015 |
Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder; Female; Humans; Ketamine; Male; Middl | 2016 |
Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2016 |
[Effects of ketamine, imipramine, and their combination on depression-like behaviors in Wistar Kyoto rats].
Topics: Animals; Brain; Depression; Depressive Disorder; Disease Models, Animal; Down-Regulation; Imipramine | 2016 |
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depressive Disorder; Diabetes M | 2016 |
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depressive Disorder; Diabetes M | 2016 |
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depressive Disorder; Diabetes M | 2016 |
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depressive Disorder; Diabetes M | 2016 |
PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Bindi | 2016 |
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease | 2016 |
Involvement of the agmatinergic system in the depressive-like phenotype of the Crtc1 knockout mouse model of depression.
Topics: Agmatine; Animals; Behavior, Animal; Blotting, Western; Brain; Brain-Derived Neurotrophic Factor; Ce | 2016 |
Interactive effects of ghrelin and ketamine on forced swim performance: Implications for novel antidepressant strategies.
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Drug Interactions; Drug Therapy, Co | 2018 |
Ketamine for Depression: An Update.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine | 2016 |
Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles.
Topics: Amygdala; Animals; Brain; Depressive Disorder; Hippocampus; Imipramine; Ketamine; Mice; Mice, Inbred | 2017 |
Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Topics: Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Receptors, N-Methyl-D-Aspa | 2016 |
Ketamine Mechanism of Action: Separating the Wheat from the Chaff.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Humans; Ketamine | 2017 |
(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Dominance-Subordination | 2017 |
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Interactions; Drug Therapy, Co | 2017 |
Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.
Topics: Adult; Cognition Disorders; Delusions; Depressive Disorder; Dissociative Disorders; Dose-Response Re | 2010 |
Commentary on Morgan et al. (2010): ketamine abuse: first medical evidence of harms we should confront.
Topics: Delusions; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Illicit Drugs; Ketamine; | 2010 |
[Ketamine in melancholic depression].
Topics: Adult; Analgesics; Anesthetics, Dissociative; Depressive Disorder; Depressive Disorder, Major; Human | 2010 |
[Ketamine in melancholic depression].
Topics: Analgesics; Depressive Disorder; Humans; Ketamine | 2010 |
Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.
Topics: Administration, Oral; Aged; Analgesics; Antidepressive Agents; Anxiety; Depressive Disorder; Dose-Re | 2010 |
Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines?
Topics: Anesthetics, Dissociative; Depressive Disorder; Electroencephalography; Female; Humans; Ketamine; Ma | 2011 |
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Humans; Injections, Intravenous; Ketamine | 2012 |
Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cross-Over Studies; Depressive Diso | 2012 |
[Effect of sub-anaesthetic doses of ketamine in the postoperative period in a patient with uncontrolled depression].
Topics: Adenocarcinoma; Analgesics; Antidepressive Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; | 2013 |
Methoxetamine: from drug of abuse to rapid-acting antidepressant.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Bipolar Disorder; Cyclohexanones; Cyclohe | 2012 |
The complexities of depression.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Brain; Depressive Disor | 2012 |
HCN1 channels: a new therapeutic target for depressive disorders?
Topics: Anesthetics, Dissociative; Animals; Brain-Derived Neurotrophic Factor; Cyclic Nucleotide-Gated Catio | 2012 |
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Enzym | 2013 |
NMDA receptors offer more than one functionality.
Topics: Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine; Pain Measurement; Pain, Po | 2003 |
Antidepressant effect of ketamine during ECT.
Topics: Anesthesia; Anesthetics; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Fema | 2005 |
Antidepressant effect of ketamine during ECT.
Topics: Anesthesia; Anesthetics; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Fema | 2005 |
Antidepressant effect of ketamine during ECT.
Topics: Anesthesia; Anesthetics; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Fema | 2005 |
Antidepressant effect of ketamine during ECT.
Topics: Anesthesia; Anesthetics; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Fema | 2005 |
Searching for rational anti N-methyl-D-aspartate treatment for depression.
Topics: Cognition Disorders; Depressive Disorder; Excitatory Amino Acid Antagonists; Humans; Ketamine; N-Met | 2007 |